Board of Directors

Board of Directors

  • W. Humphries

    William D. Humphries

    Chairman of the Board

    Mr. Humphries has served as a director of our company since January 2012 and became the chairman of our board of directors in February 2018. Since January 2017, he has served as Executive Vice President, Ortho Dermatologic. From March 2012 to December 2016, he served as President and Chief Executive Officer of the North American business of Merz, Inc., an affiliate of Merz Pharma Group, a specialty healthcare company. From 2006 to March 2012, he served in a number of leadership positions with Stiefel Laboratories, Inc., a dermatology pharmaceutical company, including as its Chief Commercial Officer and then as its President beginning in 2008. Stiefel was acquired by GlaxoSmithKline in 2009. After the acquisition, Mr. Humphries served as the President of Dermatology for Stiefel from 2009 until March 2012. Before Stiefel, Mr. Humphries served in executive roles in sales and marketing, business development, and international marketing for Allergan, Inc., concluding as vice president of its U.S. skincare business. Mr. Humphries currently serves on the board of Aclaris Therapeutics, Inc., a publicly traded company. Mr. Humphries has served on the board of ZARS Pharma, the GlaxoSmithKline Portfolio Investment Board and the GlaxoSmithKline Ophthalmology Board. Mr. Humphries received his M.B.A. degree from Pepperdine University and a B.A. degree from Bucknell University. Our board of directors believes that Mr. Humphries’ experience as pharmaceutical company executive provides him with the qualifications and skills to serve as a director of our company.

  • Richard Croarkin

    Richard Croarkin

    Former SVP, CFO, Corporate Strategy Officer, Alcon, Inc.

    Mr. Croarkin served as the Chief Financial Officer of Nestlé Health Science S.A., a division of Nestlé focused on medicalized nutrition solutions for chronic medical conditions. Prior to this, Mr. Croarkin was Senior Vice President of Finance, Chief Financial Officer & Corporate Strategy Officer at Alcon, Inc., which was the world’s leading ophthalmic pharmaceutical and medical device company before its acquisition by Novartis in 2011. Before Alcon, Mr. Croarkin served as EVP and CFO of Nestlé Waters North America after working for Pepsico Incorporated for 11 years where he served in several global senior financial positions including Chief Financial Officer of Pepsi-Cola Latin America and Pepsi-Cola Canada. Mr. Croarkin began his career with AMAX, Inc. where he worked in treasury, corporate development and planning. He holds a BA in Economics from Georgetown University, an MBA in Finance from the University of Connecticut and a Diploma in French language from Alliance Francaise in Paris, France. Mr. Croarkin is currently a Director on the Board of Aerie Pharmaceuticals, Inc. and also serves as a panelist on the NASDAQ Listing Qualifications Panel.
    Financial Expert
  • Jeffrey L. Edwards

    Jeffrey L. Edwards

    Board Member

    Mr. Edwards has served as a director of our company since September 2018. Mr. Edwards retired from Allergan, Inc. in February 2015 after nearly 22 years at the Company. Mr. Edwards served as Executive Vice President, Finance and Business Development, Chief Financial Officer of Allergan, Inc. from September 2005 to August 2014. From 2003 to 2005, Mr. Edwards served as Allergan’s Corporate Vice President, Corporate Development and previously served as Senior Vice President, Treasury, Tax and Investor Relations. Prior to joining Allergan, Mr. Edwards was with Banque Paribas and Security Pacific National Bank, where he held various senior-level positions in the credit and business development functions. Mr. Edwards currently serves on the board of directors and Compensation Committee chairman of Bio-Rad Laboratories, Inc., a publicly traded medical device company, as well as on the board of directors and as Audit Committee chairman of both FibroGen, Inc, a publicly traded biopharmaceutical company. Mr. Edwards received a Bachelor of Arts degree in Sociology from Muhlenberg College and completed the Advanced Management Program at the Harvard Business School.
  • Lasezkay

    George Lasezkay, Pharm.D., J.D.

    Board Member

    Dr. Lasezkay has served as a director of our company since August 2017. Dr. Lasezkay has an accomplished history of success in the life sciences industry. For the past 15 years, he has served as an independent director on the boards of a number of domestic and foreign emerging biopharmaceutical companies, both public and private. Dr. Lasezkay currently serves on the board of directors of TheraVida, Inc., a clinical stage drug development company. Previously, Dr. Lasezkay served as Executive Vice President, General Counsel at Acucela Inc., a development stage company that specializes in identifying and developing novel ophthalmic therapeutics. For the 12 years prior to joining Acucela, he was President of Horizon Pharma Group, a private life sciences consultancy practice. Prior to his private consultancy practice, Dr. Lasezkay was Corporate Vice President for Corporate Development at Allergan, Inc., the global pharmaceutical and medical aesthetics company. His 13 years of progressive experience at Allergan includes a number of executive leadership positions, including being a member of the company’s Executive Committee, Assistant General Counsel for Commercial Affairs, and General Counsel for the Asia-Pacific Region. In these positions, he played a critical role in developing corporate strategy and was responsible for a wide variety of licensing, R&D collaboration and acquisition transactions involving new technologies, products and companies. Earning B.S. Pharmacy and Doctor of Pharmacy degrees from the State University of New York at Buffalo, and a J.D. degree from the Southern California Gould School of Law, Dr. Lasezkay also has a multi-disciplinary background in private firm and in-house legal practice, hospital pharmacy practice, clinical pharmacokinetics consultation and clinical drug research. Our board of directors believes that Dr. Lasezkay’s unique combination of clinical, legal and executive expertise, and his diverse experience working with a number of emerging biopharmaceutical companies provides him with the qualifications and skills to serve as a director of our company.

    • Christy Shaffer, Ph.D.

      Christy Shaffer, Ph.D.

      Venture Partner and Managing Director, Hatteras Discover

      Dr. Shaffer has served as a director of our company since January 2012. Since 2011, Dr. Shaffer has served as a Venture Partner with Hatteras Venture Partners, an investment firm, and as Managing Director of Hatteras Discovery, which invests in early-stage companies in the life sciences industry sector. From 1995 to March 2010, Dr. Shaffer served in increasing leadership positions at Inspire Pharmaceuticals, a publicly held biopharmaceutical company, beginning as the company’s first full-time employee and Director of Clinical Operations and eventually being appointed as Chief Executive Officer and a director of the company in 1999, as its President in 2005 and a member of its Development Committee in 2009. Prior to Inspire, she was a clinical research scientist, international project leader and Associate Director of Pulmonary and Critical Care Medicine at Burroughs Wellcome Co. Dr. Shaffer currently serves in leadership roles on several non-profit boards, including as chair of the Morehead Planetarium and Science Center’s advisory board, on the Board of Trustees for the Cystic Fibrosis Foundation, and as chair of the board of CFF Therapeutic, Inc. Dr. Shaffer is a receptor pharmacologist by training, earning her Ph.D. in Pharmacology from the University of Tennessee’s Health Science Center in Memphis, Tennessee. She completed post-doctoral training at The Chicago Medical School as well as the University of North Carolina at Chapel Hill.
    • Clay Thorp

      Clay B. Thorp

      General Partner, Hatteras Venture Partners

      Mr. Thorp has served as a director of our company since January 2012. In 2001, Mr. Thorp co-founded and has since served as General Partner of Hatteras Venture Partners, an investment firm, where he leads investments in a range of life science companies in the biopharmaceutical, medical device, diagnostics and research informatics sectors. Previously, he was instrumental in the founding of several life sciences companies, including serving as co-founder, Chief Executive Officer and Chairman of Synthematix, Inc., a chemistry informatics company that was acquired by Symyx Technologies in 2005, co-founder and former Chairman of PhaseBio Pharmaceuticals, Inc., co-founder and head of corporate development for Novalon Pharmaceutical Corporation, which was sold to Karo Bio in 2000, and co-founder and president of Xanthon, Inc., a bioinformatics company with electro-chemical detection technology for direct analysis of DNA, RNA and proteins. Mr. Thorp holds a Masters of Public Policy from Harvard University and a B.A. degree in Mathematics and History from the University of North Carolina at Chapel Hill.
    • Daniel White

      Daniel H. White

      President and Chief Executive Officer

      Mr. White is the founder of our company and has served as our President and Chief Executive Officer and as a member of our board of directors since our inception in May 2011. From 2008 to 2011, Mr. White served as Executive Director, Global Corporate Development, for Stiefel Laboratories, Inc., a dermatology pharmaceutical company acquired by GlaxoSmithKline in 2009. From 2007 to 2008, he co-founded and served as President and Chief Executive Officer of Percept BioScience, Inc., a biotechnology company. In 2003, Mr. White co-founded, and until 2007 served as Vice President of Finance and Corporate Development of Alimera Sciences, Inc., a biopharmaceutical company focused on ophthalmology. Previously he was Head of Business Development and Licensing for CIBA Vision, a Novartis company, and Director of Licensing and Business Development for AAIPharma. Mr. White holds an M.B.A. degree from Wake Forest University and a B.S. degree in molecular biology from Auburn University.

      Join our team at Clearside

      Learn more about career opportunities and benefits at Clearside Biomedical.


      Investor Menu